Structure Therapeutics Inc. - American Depositary Shares (GPCR)
74.20
+39.64 (114.70%)
NASDAQ · Last Trade: Dec 8th, 3:10 PM EST
Detailed Quote
Previous Close
34.56
Open
45.33
Bid
74.00
Ask
74.40
Day's Range
44.74 - 94.90
52 Week Range
13.22 - 40.29
Volume
16,855,878
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,302,845
Chart
About Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Structure Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of innovative therapies targeting G protein-coupled receptors (GPCRs), which are essential in mediating various physiological processes and diseases. By leveraging advanced structural biology and computational techniques, the company aims to design small molecule treatments for a range of conditions, including metabolic disorders and neurodegenerative diseases. Through its research efforts, Structure Therapeutics strives to create effective and targeted therapeutics that can improve patient outcomes and contribute to advancements in personalized medicine. Read More
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.
The obesity treatment market is exploding, with Goldman Sachs projecting it to reach $130 billion by 2030. Driven by rising global obesity rates—now at 42% of U.S. adults, per the CDC—the sector has become a magnet for investors seeking exposure to transformative medicine.
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June.
